The PCWP Add-On represents the third FDA clearance for the CorVista System, a novel cardiopulmonary platform used at the point of care Elevated pulmonary capillary wedge pressure (PCWP) is a key ...
BETHESDA, Md., March 31, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced a poster presentation showcasing preliminary results of its machine learning-based algorithm for non-invasively ...
The US Food and Drug Administration (FDA) has cleared a new add-on test for CorVista Health's cardiopulmonary diagnostic platform to identify patients with elevated pulmonary capillary wedge pressure ...
Please provide your email address to receive an email when new articles are posted on . Dapagliflozin reduced left heart filling pressures at rest and during exercise in adults with HFpEF. The data ...
Please provide your email address to receive an email when new articles are posted on . Sublingual nitroglycerin reduced pulmonary capillary wedge pressure in patients with HF with preserved ejection ...
Empagliflozin therapy for 12 weeks resulted in a significant reduction of pulmonary capillary wedge pressure (PCWP), across all exercise loads, compared with placebo, among patients with stable ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. The PCWP Add-On represents the third FDA clearance ...
CorVista Health and Analytics For Life today announced FDA clearance of the CorVista® System with Pulmonary Capillary Wedge Pressure (PCWP) Add-On. The PCWP Add-On uses an AI-based algorithm to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results